Abstract:Modeling clinically relevant tissue responses using cell models poses a significant challenge for drug development, in particular for drug induced liver injury (DILI). This is mainly because existing liver models lack longevity and tissue-level complexity which limits their utility in predictive toxicology. In this study, we established and characterized novel bioprinted human liver tissue mimetics comprised of patient-derived hepatocytes and non-parenchymal cells in a defined architecture. Scaffold-free assembly of different cell types in an in vivo-relevant architecture allowed for histologic analysis that revealed distinct intercellular hepatocyte junctions, CD31+ endothelial networks, and desmin positive, smooth muscle actin negative quiescent stellates. Unlike what was seen in 2D hepatocyte cultures, the tissues maintained levels of ATP, Albumin as well as expression and drug-induced enzyme activity of Cytochrome P450s over 4 weeks in culture. To assess the ability of the 3D liver cultures to model tissue-level DILI, dose responses of Trovafloxacin, a drug whose hepatotoxic potential could not be assessed by standard pre-clinical models, were compared to the structurally related non-toxic drug Levofloxacin. Trovafloxacin induced significant, dose-dependent toxicity at clinically relevant doses (≤ 4uM). Interestingly, Trovafloxacin toxicity was observed without lipopolysaccharide stimulation and in the absence of resident macrophages in contrast to earlier reports. Together, these results demonstrate that 3D bioprinted liver tissues can both effectively model DILI and distinguish between highly related compounds with differential profile. Thus, the combination of patient-derived primary cells with bioprinting technology here for the first time demonstrates superior performance in terms of mimicking human drug response in a known target organ at the tissue level.

Three-dimensional (3D) liver cell models - a tool for bridging the gap between animal studies and clinical trials when screening liver accumulation and toxicity of nanobiomaterials

Three-dimensional liver models: state of the art and their application for hepatotoxicity evaluation

Development of novel tools for the in vitro investigation of drug-induced liver injury

Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In Vitro

Three-dimensional Culture of Hepatocytes for Prediction of Drug-Induced Hepatotoxicity

Three-Dimensional Cell Co-Culture Liver Models and Their Applications in Pharmaceutical Research

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

Current Perspective: 3D Spheroid Models Utilizing Human-Based Cells for Investigating Metabolism-Dependent Drug-Induced Liver Injury

Toolbox for creating three-dimensional liver models

Liver organoid as a 3D in vitro model for drug validation and toxicity assessment

Grafting of 3D Bioprinting to in Vitro Drug Screening: A Review

Three-dimensional cell culture model for hepatocytes opens a new avenue of real world research on liver

Current Research Trends in the Application of In Vitro Three-Dimensional Models of Liver Cells

Advances in 3D Cell Culture for Liver Preclinical Studies.

3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration

Biomimetic 3D Tissue Models for Advanced High-Throughput Drug Screening

Advantages of in vitro 3D liver model in study of liver toxicity

Recent advances in the development of in vitro liver models for hepatotoxicity testing

Advanced three‐dimensional in vitro liver models to study the activity of anticancer drugs

Current Advances on 3D‐Bioprinted Liver Tissue Models

Beyond the hype and toward application: liver complex in vitro models in preclinical drug safety